Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of CaCP29 in early septic organ dysfunction
2013-001037-40Phase 2Completed
- Sponsor
- InflaRx
- Start
- Aug 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vilobelimab in sepsis (4 arms), sponsored by InflaRx. Primary endpoints: Safety and tolerability, Pharmacokinetics and 1 more. Started Aug 2013; status: completed.
02
Drugs
vilobelimab
03
Conditions
sepsis
Beyond the preview
Go deeper on 2013-001037-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001037-40.